Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | PYGL | P06737 | 11/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.48 |
| ▸ | CHAT | P28329 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.42 |
| ▸ | GUSB | P08236 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | KDM4B | O94953 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3743993 | 1.00 | ALDH1A1 (0.57) | ALDH1A1CYP3A4RECQLPYGLGRIK1 | |
| Acetic Acid SCHEMBL6974964 | 0.89 | GRIK1 (0.51) | ALDH1A1CYP3A4RECQLPYGLGRIK1 | |
| SCHEMBL14143279 | 0.84 | ALDH1A1 (0.69) | ALDH1A1CYP3A4RECQLPYGLGRIK1 | |
| SCHEMBL14833783 | 0.84 | PYGL (0.47) | ALDH1A1CYP3A4RECQLPYGLGRIK1 | |
| SCHEMBL9049523 | 0.84 | PYGL (0.47) | ALDH1A1CYP3A4RECQLPYGLGRIK1 | |
| SCHEMBL28581555 | 0.82 | ALDH1A1 (0.52) | ALDH1A1CYP3A4RECQLPYGLGRIK1 | |
| SCHEMBL15260940 | 0.82 | ALDH1A1 (0.52) | ALDH1A1CYP3A4RECQLPYGLGRIK1 | |
| SCHEMBL18906796 | 0.82 | ALDH1A1 (0.52) | ALDH1A1CYP3A4RECQLPYGLGRIK1 | |
| SCHEMBL15229162 | 0.82 | ALDH1A1 (0.52) | ALDH1A1CYP3A4RECQLPYGLGRIK1 | |
| SCHEMBL4168798 | 0.81 | ALDH1A1 (0.50) | ALDH1A1CYP3A4PYGLGRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | claimed |
| US-10590085-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-17 | — | — | US | disclosed |
| US-20180134665-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
| US-20110218343-A1 | SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY | GLIAMED, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-7960570-B2 | Small molecule inhibitors of rotamase enzyme activity | GLIAMED, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7855292-B2 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-21 | — | — | US | disclosed |
| US-20100292240-A1 | SULFONAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20100145071-A1 | SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY | GLIAMED, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-7652060-B2 | Neurotrophic N-glyoxyl-prolyl ester compounds e.g. 3-phenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate; non-immunosuppressive; side effect reduction; neurodegenerative diseases | Glia Med, Inc (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
| EP-0823896-A1 | SUBSTITUTED OXIMES, HYDRAZONES AND OLEFINS AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1998-02-18 | — | — | EP | disclosed |
| US-5696267-A | ANTIHISTAMINES; ANTIINFLAMMATORY AGENTS; GASTROINTESTINAL DISORDERS | SCHERING CORPORATION (US) | 1997-12-09 | — | — | US | disclosed |
| US-5691362-A | ANTIHISTAMINES, BRONCHODILATORS, ANTIINFLAMMATORY AGENTS, GASTROINTESTINAL DISORDERS | SCHERING-PLOUGH CORPORATION (US) | 1997-11-25 | — | — | US | disclosed |
| US-5614547-A | Small molecule inhibitors of rotamase enzyme | GUILFORD PHARMACEUTICALS INC. (US) | 1997-03-25 | — | — | US | disclosed |
| WO-1996039383-A1 | SUBSTITUTED BENZENE-FUSED HETERO- AND CARBOCYCLICS AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996034857-A1 | SUBSTITUTED OXIMES, HYDRAZONES AND OLEFINS AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1996-11-07 | — | — | WO | disclosed |
| EP-0553081-B1 | PESTICIDES | ROUSSEL UCLAF (FR) | 1996-02-28 | — | — | EP | disclosed |
| US-5089639-A | N-CYCLOALKYLALKYLAMINES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A MEDICAMENT AND THEIR SYNTHESIS INTERMEDIATES | JOUVEINAL S.A. (FR) | 1992-02-18 | — | — | US | disclosed |
| US-5034419-A | Psychological disorders or gastrointestinal disorders | L'OREAL (FR) | 1991-07-23 | — | — | US | disclosed |
| US-5017723-A | Psychotropic Agents | JOUVEINAL S.A. (FR) | 1991-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145071-A1 | SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY | FKBP8, FKBP1A, FKBP2 | ALDH1A1 2906/4885CYP3A4 3661/4885RECQL 4345/4885 |
| US-10590085-B2 | Heterocyclic amides as kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | ALDH1A1 1542/4885CYP3A4 2069/4885RECQL 1407/4885 |
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | TRPV1, TRPV2, TRPV3 | ALDH1A1 502/4885CYP3A4 796/4885RECQL 2864/4885 |
| US-20100292240-A1 | SULFONAMIDE COMPOUNDS | CCKAR, CCKBR, TAS1R2 | ALDH1A1 2749/4885CYP3A4 4129/4885RECQL 4648/4885 |
| US-20110218343-A1 | SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY | FKBP8, FKBP1A, FKBP2 | ALDH1A1 2906/4885CYP3A4 3661/4885RECQL 4345/4885 |
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | TRPV1, TRPV5, TRPV2 | ALDH1A1 550/4885CYP3A4 735/4885RECQL 2106/4885 |
| US-20180134665-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | ALDH1A1 1542/4885CYP3A4 2069/4885RECQL 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.